SELP

Summary

SELP (selectin P, HGNC:10721) is a protein-coding gene on chromosome 1q24.2, encoding P-selectin (P16109). Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes.

This gene encodes a 140 kDa protein that is stored in the alpha-granules of platelets and Weibel-Palade bodies of endothelial cells. This protein redistributes to the plasma membrane during platelet activation and degranulation and mediates the interaction of activated endothelial cells or platelets with leukocytes. The membrane protein is a calcium-dependent receptor that binds to sialylated forms of Lewis blood group carbohydrate antigens on neutrophils and monocytes. Alternative splice variants may occur but are not well documented.

Source: NCBI Gene 6403 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 137 total — 1 likely-pathogenic
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_003005

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10721
Approved symbol	SELP
Name	selectin P
Location	1q24.2
Locus type	gene with protein product
Status	Approved
Aliases	CD62, PSEL, PADGEM, GMP140, CD62P, GMP-140
Ensembl gene	ENSG00000174175
Ensembl biotype	protein_coding
OMIM	173610
Entrez	6403

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 29 protein_coding, 1 retained_intron

ENST00000263686, ENST00000367786, ENST00000367788, ENST00000367795, ENST00000426706, ENST00000458599, ENST00000466167, ENST00000909597, ENST00000909598, ENST00000909599, ENST00000909600, ENST00000909601, ENST00000909602, ENST00000909603, ENST00000909604, ENST00000909605, ENST00000909606, ENST00000909607, ENST00000909608, ENST00000909609, ENST00000909610, ENST00000958021, ENST00000958022, ENST00000958023, ENST00000958024, ENST00000958025, ENST00000958026, ENST00000958027, ENST00000958028, ENST00000958029

RefSeq mRNA: 1 — MANE Select: NM_003005 NM_003005

CCDS: CCDS1282

Canonical transcript exons

ENST00000263686 — 17 exons

Exon	Start	End
ENSE00000450611	169595925	169596134
ENSE00000450613	169593605	169593724
ENSE00000789623	169609504	169609689
ENSE00000789625	169612217	169612402
ENSE00000789626	169612929	169613114
ENSE00000814471	169617028	169617414
ENSE00000814474	169613586	169613693
ENSE00000814478	169611492	169611677
ENSE00000814480	169606949	169607134
ENSE00000814484	169596991	169597176
ENSE00000958551	169594692	169594877
ENSE00001168517	169591426	169591456
ENSE00001172331	169619129	169619219
ENSE00001359830	169588849	169589461
ENSE00001445625	169630072	169630124
ENSE00003693678	169590147	169590202
ENSE00003784487	169603026	169603211

Expression profiles

Bgee: expression breadth ubiquitous, 191 present calls, max score 90.88.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.7190 / max 61.4620, expressed in 166 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
15852	0.5515	150
15851	0.1676	75

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right coronary artery	UBERON:0001625	90.88	gold quality
monocyte	CL:0000576	89.51	gold quality
mononuclear cell	CL:0000842	89.19	gold quality
left uterine tube	UBERON:0001303	88.70	gold quality
leukocyte	CL:0000738	88.53	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	87.72	gold quality
omental fat pad	UBERON:0010414	87.03	gold quality
peritoneum	UBERON:0002358	86.96	gold quality
upper lobe of left lung	UBERON:0008952	86.90	gold quality
mucosa of stomach	UBERON:0001199	86.74	gold quality
gall bladder	UBERON:0002110	86.24	gold quality
upper lobe of lung	UBERON:0008948	85.78	gold quality
adipose tissue of abdominal region	UBERON:0007808	85.36	gold quality
left coronary artery	UBERON:0001626	84.32	gold quality
metanephros cortex	UBERON:0010533	84.21	gold quality
coronary artery	UBERON:0001621	84.20	gold quality
endocervix	UBERON:0000458	83.61	gold quality
vermiform appendix	UBERON:0001154	83.42	gold quality
subcutaneous adipose tissue	UBERON:0002190	83.30	gold quality
body of uterus	UBERON:0009853	82.97	gold quality
apex of heart	UBERON:0002098	82.11	gold quality
smooth muscle tissue	UBERON:0001135	81.78	gold quality
right atrium auricular region	UBERON:0006631	81.54	gold quality
right lung	UBERON:0002167	81.36	gold quality
ileal mucosa	UBERON:0000331	81.29	silver quality
lung	UBERON:0002048	80.98	gold quality
tibial nerve	UBERON:0001323	80.97	gold quality
ectocervix	UBERON:0012249	80.93	gold quality
cardiac atrium	UBERON:0002081	80.64	gold quality
tendon of biceps brachii	UBERON:0008188	80.33	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-HCAD-11	yes	350.93
E-CURD-6	yes	221.57
E-GEOD-135922	yes	43.55
E-ANND-3	yes	29.47
E-MTAB-8410	yes	19.26
E-HCAD-10	yes	17.30
E-MTAB-10137	yes	12.36
E-MTAB-9067	yes	10.84

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

38 targeting SELP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-609	99.82	64.26	505
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-548AG	99.77	69.25	1492
HSA-MIR-4465	99.71	72.56	2096
HSA-MIR-548AI	99.69	69.24	1494
HSA-MIR-548BA	99.69	69.14	1514
HSA-MIR-570-5P	99.69	69.24	1494
HSA-MIR-580-3P	99.67	69.23	1841
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-671-5P	99.52	67.11	1277
HSA-MIR-6815-3P	99.13	68.98	1530
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-608	98.93	67.83	2013
HSA-MIR-583	98.71	67.44	1791
HSA-MIR-653-3P	98.31	67.71	1542
HSA-MIR-3179	98.22	65.90	1445
HSA-MIR-3664-3P	97.85	67.62	1452

Literature-anchored findings (GeneRIF, showing 40)

• changes in the CD62 expression induced by a drug, namely clopidogrel, or by a disease, namely diabetes, are paralleled by changes in PDGF secretion (PMID:11861803)
• Heparin blocks P-selectin-mediated interactions of endogenous platelets with sialylated fucosylated mucins on circulating carcinoma cells and this reduces tumor cell survival. (PMID:11885026)
• results showed that sP-selectin and sE-selectin levels were higher in patients with lung cancer compared to normal donors; increased levels of sP-selectin and sE-selectin were associated with squamous lung cancer at late stages but not adenocarcinoma (PMID:11936588)
• Eosinophil interaction with endothelial P-selectin is far more important than interaction with E-selectin for recruitment into the inflamed skin of patients with atopic dermatitis. (PMID:11981814)
• Hypercholesterolemia primes platelets for recruitment via VWF, GPIb alpha, and P-selectin to lesion-prone sites, before lesions are detectable. (PMID:12036879)
• Attachment of the PSGL-1 cytoplasmic domain to the actin cytoskeleton is essential for leukocyte rolling on P-selectin. (PMID:12036880)
• Specific haplotypes of the P-selectin gene are associated with myocardial infarction. (PMID:12165563)
• Conjunctival biopsies excised from patients following cataract surgery provided circumstantial evidence that endothelial P-selectin might play a role in the surgery-induced up-regulation of leukocyte rolling. (PMID:12200386)
• thrombin stimulated rapid expression of P-selectin on the surface of endothelial cells was accompanied by qualitatively parallel increases in reactive oxygen species generation (PMID:12384485)
• levels in children with acute and chronic idiopathic thrombocytopenic purpura and its relationship with mega-dose methylprednisolone therapy (PMID:12468916)
• Role of P-selectin in the adhesion of platelets to intestinal venules during ischemia/reperfusion of the intestine in mice. (PMID:12736150)
• tested hypothesis that patients with systemic sclerosis would have raised levels of soluble SELP and that there would be a relationship with autoantibodies (PMID:12757775)
• The novel varepsilon and eta and atypical zeta, but not the conventional alpha and beta and the novel delta PKCs, may be involved in the signaling pathways involved in thrombin-induced human platelet P-selectin expression (PMID:12783114)
• A novel dual role for P-selectin is revealed in its enhancement of the generation of CD14+CD16+ dendritic-like cells but inhibition of macrophage differentiation from human peripheral blood monocytes. (PMID:12847232)
• Data show that chimeras of P-selectin and immunoglobulin (P-sel-Ig) induced formation of procoagulant microparticles in human blood through P-selectin glycoprotein ligand-1. (PMID:12858167)
• Platelet P-selectin is independently associated with atherosclerotic arterial wall changes in human subjects (PMID:12860908)
• The P-selectin cytoplasmic domain directs the cellular storage of a recombinant chimeric factor IX. (PMID:12871503)
• P-selectin bound to heparin with dissociation constant, k(D), of 115 +/- 6 nM. The very slow k(off) and the reduced k(on), but apparently not the K(d), are responsible for adhesion, but not rolling of A375 cells, to P-selectin under flow. (PMID:12888879)
• P-selectin elevation in chronic liver disease may suggest a possible pathogenetic role in the course of liver cirrhosis. (PMID:12945872)
• The formation of monocyte clusters is mediated by platelet-expressed P-selectin and monocyte-expressed PSGL-1. (PMID:14615387)
• P-selectin may anchor ultralarge von willebrand factor strings to endothelial cells and facilitate their cleavage by ADAMTS13. (PMID:14630802)
• Thrombin decreased the recruitment of P-selectin into clathrin-coated pits, slowed the internalization of P-selectin, and reduced neutrophil rolling on P-selectin. (PMID:14676308)
• conclusion, NMSO3 acts as a specific inhibitor for P-selectin-mediated cell adhesion and for adhesion-dependent leukocyte activation. (PMID:14680834)
• Selectin P gene polymorphisms is associated with incident stroke (PMID:14681304)
• maximal P-selectin translocation and subsequent neutrophil adhesion was mediated by VEGF-A(165) on the activation of VEGFR-2/NRP-1 complex and required PAF synthesis. (PMID:14764537)
• P-selectin rolling involves core 2 beta1-6-N-glucosaminyltransferase and dimerization of P-selectin glycoprotein ligand-1 (PMID:15026421)
• platelet P-selectin and microparticle PSGL-1 have roles in thrombus formation [review] (PMID:15059608)
• the adhesion receptor P-selectin has a role in hemostasis [review] (PMID:15059609)
• P-selectin may play an important inflammation-related role in plaque development. (PMID:15080580)
• Results suggest that the 6-O-sulfate group of glucosamine units in heparin is critical for the inhibition of P-selectin-mediated tumor cell adhesion. (PMID:15133030)
• platelet-activating factor or interleukin 8 acted in concert with P-selectin for further enhancing the activation of alphaMbeta2 (PMID:15217824)
• P-selectin might represent a prognostic indicator in the management of patients with colorectal canceer. (PMID:15221968)
• Freshly sorted and in vitro expanded CD62L(-) memory T cells were less responsive to allogeneic antigen stimulation than were CD62L(+) naive T cells (PMID:15231569)
• selectin-dependent inflammation-seeking properties are imprinted by epigenetic modifications upon T-cell differentiation into effector cells. (PMID:15297307)
• the orientation and length of P-selectin, E-selectin, or CD16A receptor influences its rate of encountering and binding a surface ligand but does not subsequently affect the stability of binding (PMID:15299021)
• Neither liver transplantation nor liver resection influences GPIIb/IIIa and P-selectin expression on circulating platelets. (PMID:15316595)
• a sustained rise in [Ca 2+ ]i due to an increase in the frequency and amplitude of transient calcium spiking in single platelets was dependent upon engagement of both P-selectin and FcgammaRIIA (PMID:15351857)
• neutrophils stabilize selectin-mediated rolling by rapidly adjusting tether number in response to changes in wall shear stress (PMID:15353601)
• in whites and South Asians the C allele of the Thr715Pro P-selectin polymorphism is associated with lower sP-selectin levels. Lower levels of sP-selectin were not accounted for by this polymorphism in blacks, in whom the C allele was very rare. (PMID:15543334)
• levels of soluble and platelet P-selectin are increased in acute ischemic stroke, indicating a possible role of P-selectin (PMID:15583743)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio		ENSDARG00000096787
mus_musculus	Selp	ENSMUSG00000026580
rattus_norvegicus	Selp	ENSRNOG00000002794

Paralogs (39): CFH (ENSG00000000971), SELE (ENSG00000007908), C8B (ENSG00000021852), C6 (ENSG00000039537), SEZ6 (ENSG00000063015), CFHR2 (ENSG00000080910), APOH (ENSG00000091583), SEZ6L (ENSG00000100095), SUSD6 (ENSG00000100647), SRPX (ENSG00000101955), SRPX2 (ENSG00000102359), C7 (ENSG00000112936), C9 (ENSG00000113600), PAPPA2 (ENSG00000116183), CFHR3 (ENSG00000116785), CR2 (ENSG00000117322), CD46 (ENSG00000117335), CSMD2 (ENSG00000121904), C4BPA (ENSG00000123838), C4BPB (ENSG00000123843), CFHR4 (ENSG00000134365), CFHR5 (ENSG00000134389), F13B (ENSG00000143278), SUSD4 (ENSG00000143502), C8A (ENSG00000157131), SUSD3 (ENSG00000157303), CSMD3 (ENSG00000164796), SVEP1 (ENSG00000165124), C2 (ENSG00000166278), SEZ6L2 (ENSG00000174938), PRF1 (ENSG00000180644), PAPPA (ENSG00000182752), CSMD1 (ENSG00000183117), SELL (ENSG00000188404), CD55 (ENSG00000196352), CR1L (ENSG00000197721), CR1 (ENSG00000203710), CFB (ENSG00000243649), CFHR1 (ENSG00000244414)

Protein

Protein identifiers

P-selectin — P16109 (reviewed: P16109)

Alternative names: CD62 antigen-like family member P, Granule membrane protein 140, Leukocyte-endothelial cell adhesion molecule 3, Platelet activation dependent granule-external membrane protein

All UniProt accessions (7): P16109, A0A0S2Z509, F6VVT6, Q5R341, Q5R342, Q5R345, Q5R349

UniProt curated annotations — full annotation on UniProt →

Function. Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligand recognized is sialyl-Lewis X. Mediates rapid rolling of leukocyte rolling over vascular surfaces during the initial steps in inflammation through interaction with SELPLG. Mediates cell-cell interactions and cell adhesion via the interaction with integrin alpha-IIb/beta3 (ITGA2B:ITGB3) and integrin alpha-V/beta-3 (ITGAV:ITGB3).

Subunit / interactions. Interacts with SNX17. Interacts with SELPLG/PSGL1 and PODXL2 and mediates neutrophil adhesion and leukocyte rolling. This interaction requires the sialyl-Lewis X epitope of SELPLG and PODXL2, and specific tyrosine sulfation on SELPLG. Interacts (via C-type lectin domain) with alpha-IIb/beta3 integrin ITGA2B:ITGB3 and alpha-V/beta-3 integrin ITGAV:ITGB3. Interacts with alpha5/beta1 integrin ITGA5:ITGB1 and alpha4/beta1 integrin ITGA4:ITGB.

Subcellular location. Cell membrane.

Tissue specificity. Stored in the alpha-granules of platelets and Weibel-Palade bodies of endothelial cells. Upon cell activation by agonists, P-selectin is transported rapidly to the cell surface.

Domain organisation. The C-type lectin domain is required for binding to integrins. Binding to soluble integrins alpha-V/beta-3 (ITGAV:ITGB3) and alpha-IIb/beta3 (ITGA2B:ITGB) is cation-dependent in order of preference of 1 mM Mn(2+) > Mg(2+) > Ca(2+). Binds to the allosteric site (site 2) of integrins and activates them. The interaction with integrins may mediate cell-cell interactions and cell adhesion.

Similarity. Belongs to the selectin/LECAM family.

RefSeq proteins (1): NP_002996* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000436	Sushi_SCR_CCP_dom	Domain
IPR000742	EGF	Domain
IPR001304	C-type_lectin-like	Domain
IPR002396	Selectin_superfamily	Family
IPR016186	C-type_lectin-like/link_sf	Homologous_superfamily
IPR016187	CTDL_fold	Homologous_superfamily
IPR018378	C-type_lectin_CS	Conserved_site
IPR033991	Selectin_CTLD	Domain
IPR035976	Sushi/SCR/CCP_sf	Homologous_superfamily
IPR050350	Compl-Cell_Adhes-Reg	Family

Pfam: PF00059, PF00084

UniProt features (102 total): disulfide bond 23, sequence variant 17, glycosylation site 12, domain 11, strand 11, binding site 8, mutagenesis site 6, helix 3, topological domain 2, lipid moiety-binding region 2, turn 2, signal peptide 1, chain 1, region of interest 1, short sequence motif 1, transmembrane region 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
1G1S	X-RAY DIFFRACTION	1.9
1G1Q	X-RAY DIFFRACTION	2.4
1HES	X-RAY DIFFRACTION	3
1G1R	X-RAY DIFFRACTION	3.4
1FSB	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P16109-F1	80.27	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 121; 123; 123; 124; 133; 146; 146; 147

Post-translational modifications (2): 807, 807

Disulfide bonds (23): 60–158, 131–150, 163–174, 168–183, 185–194, 200–244, 230–257, 262–306, 292–319, 324–368, 354–381, 386–430, 416–443, 448–492, 478–505, 510–554, 540–567, 572–616, 602–629, 642–686 …

Glycosylation sites (12): 54, 98, 180, 212, 219, 411, 460, 518, 665, 716, 723, 741

Mutagenesis-validated functional residues (6):

Position	Phenotype
57–58	loss of interaction with integrins. reduces cell adhesion.
95–96	enhances interaction with integrins.
99	reduced interaction with integrins.
107–108	reduced interaction with integrins.
125–126	reduced interaction with integrins.
129	impairs interaction with selplg. abolishes cell rolling on glycan ligands. disrupts interaction with glycan. does not af

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-114608	Platelet degranulation
R-HSA-202733	Cell surface interactions at the vascular wall
R-HSA-109582	Hemostasis
R-HSA-76002	Platelet activation, signaling and aggregation
R-HSA-76005	Response to elevated platelet cytosolic Ca2+

MSigDB gene sets: 280 (showing top): GSE45365_NK_CELL_VS_BCELL_UP, GOBP_REGULATION_OF_CELL_ACTIVATION, WALLACE_PROSTATE_CANCER_RACE_UP, GOBP_HETEROPHILIC_CELL_CELL_ADHESION, MODULE_255, GOBP_INFLAMMATORY_RESPONSE, GOBP_RESPONSE_TO_PEPTIDE, GOCC_SECRETORY_GRANULE, REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION, GOBP_PLATELET_ACTIVATION, GOCC_CELL_SURFACE, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, GOBP_REGULATION_OF_LEUKOCYTE_MIGRATION, GOBP_CALCIUM_DEPENDENT_CELL_CELL_ADHESION

GO Biological Process (17): positive regulation of leukocyte migration (GO:0002687), inflammatory response (GO:0006954), cell adhesion (GO:0007155), heterophilic cell-cell adhesion (GO:0007157), leukocyte cell-cell adhesion (GO:0007159), positive regulation of platelet activation (GO:0010572), calcium-dependent cell-cell adhesion (GO:0016339), response to lipopolysaccharide (GO:0032496), regulation of integrin activation (GO:0033623), response to cytokine (GO:0034097), defense response to Gram-negative bacterium (GO:0050829), leukocyte tethering or rolling (GO:0050901), positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051897), cell-cell adhesion (GO:0098609), positive regulation of leukocyte tethering or rolling (GO:1903238), leukocyte migration (GO:0050900), obsolete cell-cell adhesion via plasma-membrane adhesion molecules (GO:0098742)

GO Molecular Function (12): lipopolysaccharide binding (GO:0001530), integrin binding (GO:0005178), calcium ion binding (GO:0005509), heparin binding (GO:0008201), sialic acid binding (GO:0033691), fucose binding (GO:0042806), glycosphingolipid binding (GO:0043208), calcium-dependent protein binding (GO:0048306), oligosaccharide binding (GO:0070492), protein binding (GO:0005515), carbohydrate binding (GO:0030246), metal ion binding (GO:0046872)

GO Cellular Component (6): obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), platelet dense granule membrane (GO:0031088), platelet alpha granule membrane (GO:0031092), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Hemostasis	2
Response to elevated platelet cytosolic Ca2+	1
Platelet activation, signaling and aggregation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell-cell adhesion	3
carbohydrate derivative binding	2
binding	2
secretory granule membrane	2
positive regulation of immune system process	1
regulation of leukocyte migration	1
positive regulation of cell migration	1
leukocyte migration	1
defense response	1
cellular process	1
regulation of platelet activation	1
platelet activation	1
positive regulation of cell activation	1
response to molecule of bacterial origin	1
response to lipid	1
response to oxygen-containing compound	1
integrin activation	1
regulation of protein-containing complex assembly	1
response to peptide	1
defense response to bacterium	1
cellular extravasation	1
leukocyte adhesion to vascular endothelial cell	1
phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
positive regulation of intracellular signal transduction	1
cell adhesion	1
leukocyte tethering or rolling	1
regulation of leukocyte tethering or rolling	1
positive regulation of leukocyte adhesion to vascular endothelial cell	1
immune system process	1
cell migration	1
lipid binding	1
signaling receptor binding	1
protein-containing complex binding	1
cell adhesion molecule binding	1
metal ion binding	1
glycosaminoglycan binding	1
sulfur compound binding	1
carboxylic acid binding	1
monosaccharide binding	1

Protein interactions and networks

STRING

2668 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SELP	SELPLG	Q14242	999
SELP	VWF	P04275	999
SELP	GP1BA	P07359	998
SELP	CD24	P25063	994
SELP	CD44	P16070	993
SELP	C3	P01024	991
SELP	CD40	P25942	985
SELP	GLG1	Q92896	983
SELP	SELL	P14151	983
SELP	ITGB2	P05107	975
SELP	VCAM1	P19320	963
SELP	SNX17	Q15036	957
SELP	CD40LG	P29965	944
SELP	PTX3	P26022	931
SELP	ITGA2B	P08514	929

IntAct

11 interactions, top by confidence:

A	B	Type	Score
SELP	SELPLG	psi-mi:“MI:0407”(direct interaction)	0.800
SELP	SELPLG	psi-mi:“MI:0915”(physical association)	0.800
SELPLG	SELP	psi-mi:“MI:0407”(direct interaction)	0.800
CD24	SELP	psi-mi:“MI:0407”(direct interaction)	0.440
SELP	CD34	psi-mi:“MI:0407”(direct interaction)	0.440
	PLG	psi-mi:“MI:0914”(association)	0.350
	FN1	psi-mi:“MI:0914”(association)	0.350
	SELP	psi-mi:“MI:0914”(association)	0.350

BioGRID (17): SELP (Co-crystal Structure), SNX17 (Reconstituted Complex), SNX27 (Reconstituted Complex), SELP (Protein-peptide), SELP (Two-hybrid), SELP (Affinity Capture-Western), SELP (Positive Genetic), SELP (Reconstituted Complex), SELP (Reconstituted Complex), AP1M1 (Co-crystal Structure), SELP (Affinity Capture-Western), VCAN (Reconstituted Complex), SELP (Reconstituted Complex), SELP (Cross-Linking-MS (XL-MS)), SELP (Affinity Capture-Western)

ESM2 similar proteins: O02839, O08569, O19124, O62685, O62837, O88174, P02749, P04003, P05160, P08607, P14151, P15529, P16109, P17690, P19070, P20023, P26644, P27113, P30836, P42201, P49457, P70105, P79138, P98107, P98109, P98131, Q01102, Q03472, Q07968, Q28065, Q28768, Q2VPA4, Q5R4D0, Q60401, Q60736, Q61475, Q61476, Q63135, Q63514, Q64735

Diamond homologs: A0A1D5NSM8, A2AVA0, B3EWY9, B3EWZ3, B3EWZ8, C0HL12, C5IAW9, D3YXF5, D3YXG0, D3ZTD8, E9Q6D8, F1LW30, G1FC92, G5ECS8, O08721, O08722, P10643, P13671, P16109, P17927, P19070, P20023, P35440, P35448, P58397, P61134, P61135, P68638, P68639, P98136, Q03472, Q13591, Q28065, Q29RQ1, Q29RU4, Q2PC93, Q3UHD1, Q4LDE5, Q5RAD0, Q62217

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
SELPLG	up-regulates	SELP	binding
SELP	“up-regulates activity”	“GPIb-IX-V complex”	binding
NBEAL2	up-regulates	SELP

Disease & clinical

Clinical variants and AI predictions

ClinVar

137 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	98
Likely benign	11
Benign	14

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
180693	NM_003005.4(SELP):c.775+1G>A	Likely pathogenic

SpliceAI

2491 predictions. Top by Δscore:

Variant	Effect	Δscore
1:169590141:TCTTA:T	donor_loss	1.0000
1:169590142:CTTA:C	donor_loss	1.0000
1:169590143:TTAC:T	donor_loss	1.0000
1:169590144:TA:T	donor_loss	1.0000
1:169590145:A:C	donor_loss	1.0000
1:169590146:CCTT:C	donor_loss	1.0000
1:169590200:TGG:T	acceptor_gain	1.0000
1:169590203:C:CC	acceptor_gain	1.0000
1:169593720:TCCTG:T	acceptor_gain	1.0000
1:169593721:CCTGC:C	acceptor_gain	1.0000
1:169593722:CTG:C	acceptor_gain	1.0000
1:169593725:C:CC	acceptor_gain	1.0000
1:169597174:TGG:T	acceptor_gain	1.0000
1:169597177:C:CC	acceptor_gain	1.0000
1:169612214:CACC:C	donor_loss	1.0000
1:169612216:CCTTT:C	donor_loss	1.0000
1:169612400:CAG:C	acceptor_gain	1.0000
1:169612403:C:CC	acceptor_gain	1.0000
1:169612403:CTAAA:C	acceptor_loss	1.0000
1:169612404:T:G	acceptor_loss	1.0000
1:169612410:C:CT	acceptor_gain	1.0000
1:169612925:ATAC:A	donor_loss	1.0000
1:169612926:TAC:T	donor_loss	1.0000
1:169612928:C:CT	donor_loss	1.0000
1:169613111:CTCA:C	acceptor_gain	1.0000
1:169613115:C:CC	acceptor_gain	1.0000
1:169613581:CTCA:C	donor_loss	1.0000
1:169613582:TCA:T	donor_loss	1.0000
1:169613583:CACCG:C	donor_loss	1.0000
1:169613584:A:AC	donor_gain	1.0000

AlphaMissense

5454 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:169617074:C:A	W145C	0.999
1:169617074:C:G	W145C	0.999
1:169617076:A:G	W145R	0.999
1:169617076:A:T	W145R	0.999
1:169617158:C:A	W117C	0.999
1:169617158:C:G	W117C	0.999
1:169617206:C:A	W101C	0.999
1:169617206:C:G	W101C	0.999
1:169617036:C:G	C158S	0.998
1:169617037:A:T	C158S	0.998
1:169617236:C:A	W91C	0.998
1:169617236:C:G	W91C	0.998
1:169617329:G:C	C60W	0.998
1:169617330:C:G	C60S	0.998
1:169617331:A:T	C60S	0.998
1:169617350:C:A	W53C	0.998
1:169617350:C:G	W53C	0.998
1:169617035:A:C	C158W	0.997
1:169617117:C:G	C131S	0.997
1:169617118:A:T	C131S	0.997
1:169617225:C:G	R95P	0.997
1:169612954:C:A	W250C	0.996
1:169612954:C:G	W250C	0.996
1:169613594:C:G	C194S	0.996
1:169613595:A:T	C194S	0.996
1:169613654:C:G	C174S	0.996
1:169613655:A:T	C174S	0.996
1:169617037:A:G	C158R	0.996
1:169617116:G:C	C131W	0.996
1:169617200:C:A	W103C	0.996

dbSNP variants (sampled 300 via entrez): RS1000033133 (1:169629888 G>A), RS1000048231 (1:169594877 G>A), RS1000060349 (1:169614003 C>A), RS1000158675 (1:169600811 G>A), RS1000213362 (1:169605239 A>G,T), RS1000329474 (1:169616758 C>T), RS1000338177 (1:169623097 G>A), RS1000466747 (1:169616994 T>A,C), RS1000474664 (1:169595069 A>C), RS1000603524 (1:169610579 T>A,C), RS1000640809 (1:169605444 A>G), RS1000656004 (1:169618498 C>A,T), RS1000666933 (1:169625863 T>C), RS1000883080 (1:169632051 T>C), RS1000889281 (1:169621757 T>C)

Disease associations

OMIM: gene MIM:173610 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST000599_1	Soluble levels of adhesion molecules	4.000000e-16
GCST000599_4	Soluble levels of adhesion molecules	4.000000e-61
GCST000898_2	Total ventricular volume	3.000000e-07
GCST001530_6	Hippocampal atrophy	1.000000e-09
GCST001574_2	Activated partial thromboplastin time	3.000000e-09
GCST003043_84	Inflammatory bowel disease	3.000000e-08
GCST003815_2	Late-onset Alzheimer’s disease	6.000000e-06
GCST006585_1145	Blood protein levels	2.000000e-184
GCST009462_50	Optic disc size	4.000000e-15
GCST010107_8	L-selectin levels	5.000000e-06
GCST90002393_163	Monocyte count	1.000000e-19

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004519	soluble P-selectin measurement
EFO:0004522	adhesion molecule measurement
EFO:0005039	hippocampal atrophy
EFO:1001870	late-onset Alzheimers disease
EFO:0008202	L-Selectin measurement
EFO:0005091	monocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL3301394 (PROTEIN-PROTEIN INTERACTION), CHEMBL3831288 (PROTEIN FAMILY), CHEMBL5378 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 103,388 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1215923	BIMOSIAMOSE	2	155
CHEMBL288114	GALLIC ACID	2	103,233

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — CD molecules

Most potent curated ligand interactions (4 total), top 4:

Ligand	Action	Affinity	Parameter
crizanlizumab	Binding	8.23	pKd
selectin P ligand	Binding	6.49	pKd
bimosiamose	Binding	4.15	pIC50
rivipansel	Binding	3.37	pIC50

ChEMBL bioactivities

88 potent at pChembl≥5 of 160 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.70	IC50	2	nM	CHEMBL2303775
7.00	IC50	100	nM	CHEMBL3215365
7.00	IC50	100	nM	CHEMBL3215363
7.00	IC50	100	nM	CHEMBL3215364
7.00	IC50	100	nM	CHEMBL3215297
6.89	IC50	130	nM	CHEMBL62853
6.54	IC50	290	nM	CHEMBL302139
6.52	IC50	300	nM	CHEMBL3351094
6.52	IC50	300	nM	CHEMBL3351095
6.52	IC50	300	nM	CHEMBL3351093
6.52	IC50	300	nM	CHEMBL302139
6.52	IC50	300	nM	CHEMBL5269430
6.42	IC50	380	nM	CHEMBL2303665
6.40	IC50	400	nM	CHEMBL3215359
6.40	IC50	400	nM	CHEMBL2312649
6.38	IC50	420	nM	CHEMBL2303665
6.37	IC50	430	nM	CHEMBL2312651
6.35	IC50	450	nM	CHEMBL2303755
6.35	IC50	450	nM	CHEMBL3215516
6.30	IC50	500	nM	CHEMBL7864
6.24	IC50	580	nM	CHEMBL2311550
6.24	IC50	570	nM	CHEMBL375763
6.22	IC50	600	nM	CHEMBL3351089
6.22	IC50	600	nM	CHEMBL3215366
6.19	IC50	640	nM	CHEMBL326754
6.17	IC50	680	nM	CHEMBL2303665
6.13	IC50	740	nM	CHEMBL220720
6.06	IC50	870	nM	CHEMBL220254
6.05	IC50	900	nM	CHEMBL3215357
6.00	IC50	1000	nM	CHEMBL112485
6.00	IC50	1000	nM	CHEMBL2312654
6.00	IC50	1000	nM	PHOSPHATIDYL GLYCEROL
6.00	Kd	1000	nM	CHEMBL5560997
6.00	IC50	1000	nM	CHEMBL74108
5.96	IC50	1100	nM	CHEMBL2312648
5.96	IC50	1100	nM	CHEMBL223010
5.96	IC50	1100	nM	CHEMBL221163
5.96	Kd	1100	nM	CHEMBL6164687
5.92	IC50	1200	nM	CHEMBL3215362
5.92	IC50	1200	nM	CHEMBL2312650
5.92	IC50	1200	nM	CHEMBL2312646
5.92	IC50	1200	nM	CHEMBL373592
5.89	IC50	1300	nM	CHEMBL3215356
5.82	IC50	1500	nM	CHEMBL2312645
5.80	IC50	1600	nM	CHEMBL450011
5.80	IC50	1600	nM	CHEMBL2312653
5.77	IC50	1700	nM	CHEMBL3215368
5.72	Kd	1900	nM	CHEMBL6174071
5.68	IC50	2100	nM	CHEMBL220255
5.66	IC50	2200	nM	CHEMBL2312652

PubChem BioAssay actives

83 with measured affinity, of 554 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(2S,3S,4S,5S,6S)-2-[(2S,3R,4R,5S,6R)-6-[acetyl-[3-[2-(pentacosa-10,12-diynoylamino)ethylsulfanyl]propyl]amino]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3S,4S,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxyacetic acid	202750: Inhibitory activity against Selectin P IgG chimera binding to HL-60 cells, by binding to Selectin P	ic50	0.0020	uM
disodium;[(2R,3S,4S,5R,6S)-2-[(E,2S,3R)-2-(hexadecanoylamino)-3-hydroxyoctadec-4-enoxy]-5-hydroxy-6-(hydroxymethyl)-3-sulfonatooxyoxan-4-yl] sulfate	202748: In vitro inhibitory concentration against Selectin P in a cell-free binding assay	ic50	0.1000	uM
disodium;[(2R,3S,4S,5R,6S)-2-[(E,2S,3R)-2-(hexadecanoylamino)-3-phenylmethoxyoctadec-4-enoxy]-5-hydroxy-6-(hydroxymethyl)-3-sulfonatooxyoxan-4-yl] sulfate	202748: In vitro inhibitory concentration against Selectin P in a cell-free binding assay	ic50	0.1000	uM
disodium;[(4aS,6R,7S,8S,8aR)-6-[(E,2S,3R)-2-(hexadecanoylamino)-3-phenylmethoxyoctadec-4-enoxy]-2-phenyl-7-sulfonatooxy-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-8-yl] sulfate	202748: In vitro inhibitory concentration against Selectin P in a cell-free binding assay	ic50	0.1000	uM
disodium;[(2S,3R,4R,5S,6R)-6-[(E,2S,3R)-2-(hexadecanoylamino)-3-phenylmethoxyoctadec-4-enoxy]-4,5-bis(phenylmethoxy)-2-(sulfonatooxymethyl)oxan-3-yl] sulfate	202748: In vitro inhibitory concentration against Selectin P in a cell-free binding assay	ic50	0.1000	uM
3-[4-[4-[4-[(E)-2-carboxyethenyl]phenyl]-5-[4-[(E)-3-(hexadecylamino)-3-oxoprop-1-enyl]phenyl]-1H-imidazol-2-yl]phenyl]-1,2-oxazole-5-carboxylic acid	150743: Inhibitory activity against P-selectin using ELISA-based assay	ic50	0.1300	uM
3-[4-[5-[4-[(E)-2-carboxyethenyl]phenyl]-4-[4-[(E)-3-(hexadecylamino)-3-oxoprop-1-enyl]phenyl]-1H-imidazol-2-yl]phenyl]-4,5-dihydro-1,2-oxazole-5-carboxylic acid	150743: Inhibitory activity against P-selectin using ELISA-based assay	ic50	0.2900	uM
(4S)-5-(methylamino)-5-oxo-4-[[(2R)-2-(2-tetradecylhexadecanoylamino)-3-[(2S,3S,4S,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxypropanoyl]amino]pentanoic acid	202752: Inhibition of Selectin P binding	ic50	0.3000	uM
(4R)-5-(methylamino)-5-oxo-4-[[(2R)-2-(2-tetradecylhexadecanoylamino)-3-[(2S,3S,4S,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxypropanoyl]amino]pentanoic acid	202752: Inhibition of Selectin P binding	ic50	0.3000	uM
(4R)-5-(methylamino)-5-oxo-4-[[(2S)-2-(2-tetradecylhexadecanoylamino)-3-[(2S,3S,4S,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxypropanoyl]amino]pentanoic acid	202752: Inhibition of Selectin P binding	ic50	0.3000	uM
(E)-3-[4-[2-[4-(5-formyl-4,5-dihydro-1H-pyrazol-3-yl)phenyl]-4-[4-[(E)-3-(hexadecylamino)-3-oxoprop-1-enyl]phenyl]-1H-imidazol-5-yl]phenyl]prop-2-enoic acid	1938516: Inhibition of P-selectin (unknown origin) incubated for 30 mins by ELISA	ic50	0.3000	uM
(4R)-5-(methylamino)-5-oxo-4-[[(2S)-2-(2-tetradecylhexadecanoylamino)-3-[(2S,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropanoyl]amino]pentanoic acid	202752: Inhibition of Selectin P binding	ic50	0.3800	uM
2-(3,5-dichloroanilino)-4-[[4-(dimethylamino)cyclohexyl]amino]-N-(1-methylpiperidin-4-yl)pyrimidine-5-carboxamide	721418: Inhibition of P-selectin aggregation in platelet surface (unknown origin)	ic50	0.4000	uM
sodium [(2S,3S,4S,5S,6R)-6-[(E,2S,3R)-2-(hexadecanoylamino)-3-phenylmethoxyoctadec-4-enoxy]-3,4,5-trihydroxyoxan-2-yl]methyl sulfate	202748: In vitro inhibitory concentration against Selectin P in a cell-free binding assay	ic50	0.4000	uM
2-(3,5-dichloroanilino)-N-(1-methylpiperidin-4-yl)-4-[[(3S)-2-oxoazepan-3-yl]amino]pyrimidine-5-carboxamide	721418: Inhibition of P-selectin aggregation in platelet surface (unknown origin)	ic50	0.4300	uM
(4S)-5-(methylamino)-5-oxo-4-[[(2R)-2-(2-tetradecylhexadecanoylamino)-3-[(2S,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropanoyl]amino]pentanoic acid	202752: Inhibition of Selectin P binding	ic50	0.4500	uM
(4R)-5-(methylamino)-5-oxo-4-[[(2S)-2-(2-tetradecylhexadecanoylamino)-3-[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropanoyl]amino]pentanoic acid	202747: In vitro inhibitory activity of compound was determined against Selectin P binding by ELISA assay	ic50	0.4500	uM
N-(2-hydroxyethyl)pentacosa-10,12-diynamide	202750: Inhibitory activity against Selectin P IgG chimera binding to HL-60 cells, by binding to Selectin P	ic50	0.5000	uM
2-[5-[4-[[3-(2,3,4-trihydroxyphenyl)benzoyl]amino]phenyl]thiophen-2-yl]acetic acid	280291: Inhibition of human P-selectin after 2 hrs	ic50	0.5700	uM
2-(3,5-dichloroanilino)-4-[[(2S)-1-hydroxybutan-2-yl]amino]-N-(1-methylpiperidin-4-yl)pyrimidine-5-carboxamide	721418: Inhibition of P-selectin aggregation in platelet surface (unknown origin)	ic50	0.5800	uM
(4S)-5-(methylamino)-5-oxo-4-[[(2S)-2-(2-tetradecylhexadecanoylamino)-3-[(2S,3S,4S,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxypropanoyl]amino]pentanoic acid	202752: Inhibition of Selectin P binding	ic50	0.6000	uM
sodium [(2R,3S,4S,5R,6S)-2-[(E,2S,3R)-2-(hexadecanoylamino)-3-hydroxyoctadec-4-enoxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] sulfate	202748: In vitro inhibitory concentration against Selectin P in a cell-free binding assay	ic50	0.6000	uM
sodium [6-[(E,2S,3R)-2-(hexadecanoylamino)-3-hydroxyoctadec-4-enoxy]-3-hydroxy-2-(hydroxymethyl)oxan-4-yl] sulfate	202748: In vitro inhibitory concentration against Selectin P in a cell-free binding assay	ic50	0.6400	uM
2-[5-[3-[[3-(2,3,4-trihydroxyphenyl)benzoyl]amino]phenyl]thiophen-2-yl]acetic acid	280291: Inhibition of human P-selectin after 2 hrs	ic50	0.7400	uM
2-[3-[2-(3,4,5-trihydroxybenzoyl)oxyphenyl]phenyl]acetic acid	280291: Inhibition of human P-selectin after 2 hrs	ic50	0.8700	uM
disodium;[(2R,3S,4S,5S,6S)-2-[(E,2S,3R)-2-(hexadecanoylamino)-3-phenylmethoxyoctadec-4-enoxy]-4,5-dihydroxy-6-(sulfonatooxymethyl)oxan-3-yl] sulfate	202748: In vitro inhibitory concentration against Selectin P in a cell-free binding assay	ic50	0.9000	uM
2-[[2-[6-[4-[2-[2-(2-ethoxyethoxy)ethoxy]ethoxy]butoxymethyl]-3,4,5-trihydroxyoxan-2-yl]acetyl]-[1-[(2-methoxy-2-oxoethyl)amino]-1-oxopropan-2-yl]amino]pentanedioic acid	150775: Compound was tested in a cell-free SLe-polyacrylamide glycoconjugate binding assay (assay B) in P-selectin	ic50	1.0000	uM
2-[4-methoxy-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)phenyl]acetic acid	150890: Inhibitory activity against P-selectin IgG chimeras binding to sLex coating 96 wells using competitive cell-free ELISA assay was determined.	ic50	1.0000	uM
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate	403206: Displacement of immobilized sulfatide from P-selectin transfected in african green monkey COS cells by IgG-based competitive ELISA	ic50	1.0000	uM
2-N-(3,5-dichlorophenyl)-4-N-[4-(dimethylamino)cyclohexyl]-5-(3-methyl-1,2-oxazol-5-yl)pyrimidine-2,4-diamine	721418: Inhibition of P-selectin aggregation in platelet surface (unknown origin)	ic50	1.0000	uM
3-[[2-(3,4,5-trihydroxyphenyl)acetyl]amino]benzoic acid	280291: Inhibition of human P-selectin after 2 hrs	ic50	1.1000	uM
2-[5-[2-[[4-(2,3,4-trihydroxyphenyl)benzoyl]amino]phenyl]thiophen-2-yl]acetic acid	280291: Inhibition of human P-selectin after 2 hrs	ic50	1.1000	uM
2-[(2,5-dichlorophenyl)methylamino]-4-[[4-(dimethylamino)cyclohexyl]amino]-N-(1-methylpiperidin-4-yl)pyrimidine-5-carboxamide	721418: Inhibition of P-selectin aggregation in platelet surface (unknown origin)	ic50	1.1000	uM
5-[2-[[3-(2,3,4-trihydroxyphenyl)benzoyl]amino]phenyl]thiophene-2-carboxylic acid	280291: Inhibition of human P-selectin after 2 hrs	ic50	1.2000	uM
4-(cyclopentylamino)-2-[(2,5-dichlorophenyl)methylamino]-N-(1-methylpiperidin-4-yl)pyrimidine-5-carboxamide	721418: Inhibition of P-selectin aggregation in platelet surface (unknown origin)	ic50	1.2000	uM
2-(3,5-dichloroanilino)-N-(1-methylpiperidin-4-yl)-4-(oxan-4-ylamino)pyrimidine-5-carboxamide	721418: Inhibition of P-selectin aggregation in platelet surface (unknown origin)	ic50	1.2000	uM
disodium;[(2R,3S,4S,5S,6S)-2-[(E,2S,3R)-2-(hexadecanoylamino)-3-hydroxyoctadec-4-enoxy]-4,5-dihydroxy-6-(sulfonatooxymethyl)oxan-3-yl] sulfate	202748: In vitro inhibitory concentration against Selectin P in a cell-free binding assay	ic50	1.2000	uM
disodium;[(2R,3S,4S,5R,6S)-5-acetyloxy-2-[(E,2S,3R)-2-(hexadecanoylamino)-3-phenylmethoxyoctadec-4-enoxy]-3-phenylmethoxy-6-(sulfonatooxymethyl)oxan-4-yl] sulfate	202748: In vitro inhibitory concentration against Selectin P in a cell-free binding assay	ic50	1.3000	uM
4-(cyclopentylamino)-2-[(2-methoxyphenyl)methylamino]-N-(1-methylpiperidin-4-yl)pyrimidine-5-carboxamide	721418: Inhibition of P-selectin aggregation in platelet surface (unknown origin)	ic50	1.5000	uM
5-methoxy-5-oxo-4-[[(2R)-2-(2-tetradecylhexadecanoylamino)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxypropanoyl]amino]pentanoic acid	202752: Inhibition of Selectin P binding	ic50	1.6000	uM
2-N-(3,5-dichlorophenyl)-5-(3-methyl-1,2-oxazol-5-yl)-4-N-piperidin-4-ylpyrimidine-2,4-diamine	721418: Inhibition of P-selectin aggregation in platelet surface (unknown origin)	ic50	1.6000	uM
disodium;[(2S,3S,4R,5S,6R)-6-[(E,2S,3R)-2-(hexadecanoylamino)-3-hydroxyoctadec-4-enoxy]-4,5-dihydroxy-2-(sulfonatooxymethyl)oxan-3-yl] sulfate	202748: In vitro inhibitory concentration against Selectin P in a cell-free binding assay	ic50	1.7000	uM
2-[3-[[2-(3,4,5-trihydroxyphenyl)acetyl]amino]phenyl]acetic acid	280291: Inhibition of human P-selectin after 2 hrs	ic50	2.1000	uM
2-(3,5-dichloroanilino)-4-[[(3R,4S)-4-hydroxyoxolan-3-yl]amino]-N-(1-methylpiperidin-4-yl)pyrimidine-5-carboxamide	721418: Inhibition of P-selectin aggregation in platelet surface (unknown origin)	ic50	2.2000	uM
2-[3-[3-(3,4,5-trihydroxyphenyl)propanoylamino]phenyl]acetic acid	280291: Inhibition of human P-selectin after 2 hrs	ic50	2.3000	uM
2-[5-[2-[[2-(3,4,5-trihydroxyphenyl)acetyl]amino]phenyl]thiophen-2-yl]acetic acid	280291: Inhibition of human P-selectin after 2 hrs	ic50	2.4000	uM
disodium;[(2R,3S,4S,5R,6S)-2-[(E,2S,3R)-2-(hexadecanoylamino)-3-hydroxyoctadec-4-enoxy]-3,5-dihydroxy-6-(sulfonatooxymethyl)oxan-4-yl] sulfate	202748: In vitro inhibitory concentration against Selectin P in a cell-free binding assay	ic50	2.4000	uM
sodium [(2R,3S,4S,5S,6S)-2-[(E,2S,3R)-2-(hexadecanoylamino)-3-hydroxyoctadec-4-enoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl] sulfate	202748: In vitro inhibitory concentration against Selectin P in a cell-free binding assay	ic50	2.5000	uM
3-[(2S,5R)-3,6-dioxo-7-(2-tetradecylhexadecyl)-5-[[(2S,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-1,4,7-thiadiazecan-2-yl]propanoic acid	202747: In vitro inhibitory activity of compound was determined against Selectin P binding by ELISA assay	ic50	2.5700	uM
4-[[2-(3,4,5-trihydroxyphenyl)acetyl]amino]cyclohexane-1-carboxylic acid	280291: Inhibition of human P-selectin after 2 hrs	ic50	2.8000	uM

CTD chemical–gene interactions

69 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aspirin	decreases reaction, increases expression, decreases expression	5
Adenosine Diphosphate	increases expression, decreases reaction, affects reaction, affects localization, increases reaction	4
Resveratrol	decreases reaction, increases expression, increases reaction	3
Tretinoin	decreases expression, increases expression	3
Arachidonic Acid	increases expression, decreases reaction	3
Particulate Matter	decreases reaction, increases expression	3
titanium dioxide	decreases reaction, increases expression	2
Arsenic Trioxide	decreases expression	2
Air Pollutants	affects expression	2
Cocaine	affects localization	2
Glucose	decreases reaction, increases expression, increases response to substance	2
Heparin	affects localization, decreases reaction, increases reaction, increases expression	2
Nickel	affects expression, increases expression, decreases reaction	2
Quercetin	decreases reaction, increases expression	2
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid	increases reaction, increases expression, decreases reaction	2
Sertraline	decreases expression	2
N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide	affects cotreatment, decreases reaction, increases expression	1
parthenolide	decreases expression	1
triphenyl phosphate	affects expression	1
nylestriol	decreases expression	1
trichostatin A	affects expression, decreases reaction	1
chloramine-T	decreases expression	1
mono-(2-ethylhexyl)phthalate	decreases methylation, increases abundance	1
sodium arsenite	increases expression, increases response to substance	1
styrofoam	increases expression	1
convulxin	increases expression, decreases reaction	1
lipoxin A4	affects response to substance	1
ICI 192605	increases expression, decreases reaction	1
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione	decreases reaction, increases expression, increases reaction	1
MK-886	decreases reaction, increases expression	1

ChEMBL screening assays

100 unique, capped per target: 96 binding, 4 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3293895	Binding	Inhibition of PSEL/PSGL1 (unknown origin) interaction	Synthesis and biological evaluation of a unique heparin mimetic hexasaccharide for structure-activity relationship studies. — J Med Chem
CHEMBL751612	Functional	Compound was tested for inhibition of HL60 cell adhesion to recombinant P-selectin-IgG fusion protein obtained from transfected COS cells	Synthesis and biological activity of novel sialyl-lewisX conjugates — Bioorg Med Chem Lett

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.